Loading
SIL204 is a gene-silencing medicine from Silexion Therapeutics that stops cancer cells making the KRAS protein that drives them. It is given with chemotherapy and is in a larger trial in pancreatic cancer.
SIL204 is Silexion Therapeutics' second-generation siRNA against KRAS. It is given directly into the tumour and systemically by subcutaneous injection, together with standard chemotherapy. Silexion received Israeli and German approvals in the second quarter of 2026 for a phase 2/3 trial in locally advanced pancreatic cancer and initiated it in Tel Aviv in late July 2026. A first-generation siRNA from the company was tested with chemotherapy in an earlier phase 2 trial.
A second-generation small interfering RNA engineered to suppress expression of the KRAS oncogene, preventing production of the oncogenic protein, as described by Silexion Therapeutics. Connects to KRAS.
1.SIL204 slips into a pocket on KRAS.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"SIL204" OR ABSTRACT:"SIL204") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SIL204, not a curated reading list.
Shares KRAS and the tag pipeline.
Shares Oligonucleotide therapeutics and the tag pipeline.
Shares KRAS and the tag pipeline.
Shares KRAS and the tag pipeline.
Shares KRAS and the tag pipeline.
Shares KRAS and the tag pipeline.
Shares KRAS and the tag pipeline.
Shares KRAS and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/